a genetic medicines company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases
Industry Biotechnology
A.I.dvisor indicates that over the last year, GBIO has been loosely correlated with BEAM. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GBIO jumps, then BEAM could also see price increases.
Ticker / NAME | Correlation To GBIO | 1D Price Change % | ||
---|---|---|---|---|
GBIO | 100% | -7.58% | ||
BEAM - GBIO | 46% Loosely correlated | -8.55% | ||
NTLA - GBIO | 44% Loosely correlated | -3.65% | ||
TECH - GBIO | 44% Loosely correlated | -3.05% | ||
EDIT - GBIO | 43% Loosely correlated | -6.68% | ||
ABOS - GBIO | 42% Loosely correlated | -10.58% | ||
More |
Ticker / NAME | Correlation To GBIO | 1D Price Change % |
---|---|---|
GBIO | 100% | -7.58% |
treatment theme (61 stocks) | 45% Loosely correlated | +0.91% |
gene therapy theme (13 stocks) | 24% Poorly correlated | +1.26% |
dna theme (4 stocks) | 23% Poorly correlated | -4.05% |